In addition, recent findings indicate that immune checkpoint molecules, namely PD-1/PD-L1 and CTLA-4, which have been extensively utilized in cancer immunotherapy, are also present in the cardiovascular system and could potentially impact the progression of cardiovascular disease [6]. Here, PDCD1 is linked to cancer.